Back to top

Insulet’s EVOLVE Trial Targets Big Type 2 Diabetes Opportunity With Omnipod M

Insulet ($PODD) announced an update on their ongoing clinical study. Insulet’s new EVOLVE study, officially titled “Evaluation of the Fully Closed ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Insulet Corporation (PODD)